Early human ADME using microdoses and microtracers: bioanalytical considerations


Accelerator mass spectrometry is now increasingly used in clinical studies with a microdose of 14C-labeled drug tracing a normal clinical dose (unlabeled); this has been termed ‘microtracing’ [11,12]. This high-sensitivity microtracing has been the only practical analytical solution for certain tissue- or fluid-limited analyses (cells, biopsies and pediatrics), when radiolysis or dosimetry issues are of concern, and for the study of low systemic bioavailability routes of delivery (transdermal, ocular and pulmonary) [13,14]. One microtracing design gaining wide industrial adoption is to measure human clearance and absolute bioavailability by the simultaneous dosing of an intravenous microdose of 14C-labeled drug with a...

To view this content, please register now for access

It's completely free